A phase I pharmacological and biological study of PI-88 and docetaxel in patients with advanced malignancies

Laura Q. Chow,Daniel L. Gustafson,Cindy L. O’Bryant,Lia Gore,Michele Basche,Scott N. Holden,Mark Morrow,Stacy Grolnic,Brian R. Creese,Kaye L. Roberts,Kat Davis,R. S. Addison,S. Gail Eckhardt

A phase I pharmacological and biological study of PI-88 and docetaxel in patients with advanced malignancies

2008

Laura Q. Chow
Daniel L. Gustafson
Cindy L. O’Bryant
Lia Gore
Michele Basche
Scott N. Holden
Mark Morrow
Stacy Grolnic
Brian R. Creese
Kaye L. Roberts
Kat Davis
R. S. Addison
S. Gail Eckhardt

Purpose This study evaluated the safety, toxicity, pharmacological properties and biological activity of PI-88, a heparanase endoglycosidase enzyme inhibitor, with fixed weekly docetaxel in patients with advanced solid malignancies.

Keywords:

Clinical trial
Angiogenesis
Endoglycosidase
Toxicity
Pharmacology
Biological activity
Heparanase
Docetaxel
Medicine
Enzyme inhibitor

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations